Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (19)
Yu-Ting Lin, Tamara Will, Charlotte Wickham, Petra Boeree, Dominic Jack & Matthew Keiser. (2023) Evolution of the RebiSmart® Electromechanical Autoinjector to Improve Usability in Support of Adherence to Subcutaneous Interferon Beta-1a Therapy for People Living with Multiple Sclerosis. Patient Preference and Adherence 17, pages 1923-1933.
Read now
Read now
Uwe Klaus Zettl, Paulus Stefan Rommer, Orhan Aktas, Torsten Wagner, Joachim Richter, Patrick Oschmann, Lukas Cepek, Birte Elias-Hamp, Klaus Gehring, Andrew Chan & Michael Hecker. (2023) Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation. Expert Review of Clinical Immunology 19:11, pages 1343-1359.
Read now
Read now
Francesco Piras, Lilian Arnaud, Eric Henninger, Matthew Keiser, Andrea Seitzinger, Dominic Jack & Quentin Le Masne. (2023) Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 years. Expert Opinion on Drug Delivery 20:6, pages 863-870.
Read now
Read now
Zbyšek Pavelek, Michal Novotný, Blanka Klímová, Marek Peterka, Pavel Potužník, Martina Kövári & Martin Vališ. (2021) DORADA adherence study: full view into RebiSmart subdomains parameters in multiple sclerosis treatment. Current Medical Research and Opinion 37:4, pages 589-596.
Read now
Read now
Daljit Tatla, Irina Mountian, Boglarka Szegvari, Brenda VanLunen & Michael Schiff. (2020) A multicenter, open-label study to evaluate the safe and effective use of a new electromechanical auto-injection device for self-injection of certolizumab pegol. Expert Opinion on Drug Delivery 17:6, pages 855-862.
Read now
Read now
Martin Vališ, Jana Šarláková, Simona Halúsková, Blanka Klímová, Pavel Potužník, Marek Peterka, Kamil Kuča, Pavel Štourač, Jan Mareš & Zbyšek Pavelek. (2020) An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart®. Expert Opinion on Drug Delivery 17:5, pages 719-724.
Read now
Read now
Beate Bittner, Chantal Schmit Chiesi, Saifuddin Kharawala, Gavneet Kaur & Johannes Schmidt. (2019) Connected drug delivery devices to complement drug treatments: potential to facilitate disease management in home setting. Medical Devices: Evidence and Research 12, pages 101-127.
Read now
Read now
Scott Fettner, Christopher Mela, Florian Wildenhahn, Monica Tavanti, Christine Wells, Wendy Douglass & Navita L. Mallalieu. (2019) Evidence of bioequivalence and positive patient user handling of a tocilizumab autoinjector. Expert Opinion on Drug Delivery 16:5, pages 551-561.
Read now
Read now
Elena Didenko Pedersen, Egon Stenager, JL Vadgaard, MB Jensen, R Schmid, N Meland, G Magnussen & Jette L Frederiksen. (2018) Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study). Patient Preference and Adherence 12, pages 569-575.
Read now
Read now
Laura Dumitrescu, Cris S. Constantinescu & Radu Tanasescu. (2018) Recent developments in interferon-based therapies for multiple sclerosis. Expert Opinion on Biological Therapy 18:6, pages 665-680.
Read now
Read now
Uwe Klaus Zettl, Michael Hecker, Orhan Aktas, Torsten Wagner & Paulus S. Rommer. (2018) Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledge. Expert Review of Clinical Immunology 14:2, pages 137-153.
Read now
Read now
Sibyl Wray, Brooke Hayward, Fernando Dangond & Barry Singer. (2018) Ease of use of two autoinjectors in patients with multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: results of the randomized, crossover REDEFINE study. Expert Opinion on Drug Delivery 15:2, pages 127-135.
Read now
Read now
Andrea Zimmer, Michael Coslovsky, Ivo Abraham & Bernhard F Décard. (2017) Adherence to fingolimod in multiple sclerosis: an investigator-initiated, prospective, observational, single-center cohort study. Patient Preference and Adherence 11, pages 1815-1830.
Read now
Read now
V Limmroth, J Reischl, B Mann, X Morosov, A Kokoschka, I Weller & T Schreiner. (2017) Autoinjector preference among patients with multiple sclerosis: results from a national survey. Patient Preference and Adherence 11, pages 1325-1334.
Read now
Read now
Marieke Krol, Gert de Voer & Ulrike Osowski. (2017) Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart® injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis. Patient Preference and Adherence 11, pages 1189-1196.
Read now
Read now
María Dolores Edo Solsona, Emilio Monte Boquet, Bonaventura Casanova Estruch & José Luis Poveda Andrés. (2017) Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart® in patients with multiple sclerosis. Patient Preference and Adherence 11, pages 415-421.
Read now
Read now
Marc C. Torjman, Robert Machnicki, Jennifer Lessin, Channy Loeum, Douglas Steinberger, Sarah Mycroft & Jeffrey I. Joseph. (2017) Evaluation of an investigational wearable injector in healthy human volunteers. Expert Opinion on Drug Delivery 14:1, pages 7-13.
Read now
Read now
Peter Joseph Jongen, Wim A Lemmens, Raymond Hupperts, Erwin LJ Hoogervorst, Hans M Schrijver, Astrid Slettenaar, Els L de Schryver, Jan Boringa, Esther van Noort & Rogier Donders. (2016) Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines. Patient Preference and Adherence 10, pages 909-917.
Read now
Read now
Damiano Paolicelli, Eleonora Cocco, Valentina Di Lecce, Vita Direnzo, Lucia Moiola, Roberta Lanzillo, Paola Perini, Simona Malucchi, Giovanna Borriello, Emilio Portaccio, Valentina Panetta, Giuseppe Fenu, Francesca Sangalli, Laura Cacciaguerra & Maria Trojano. (2016) Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. Expert Opinion on Drug Delivery 13:6, pages 799-805.
Read now
Read now
Articles from other publishers (15)
Raed Al-Roughani, Magd Zakaria, Edward J. Cupler & Karim Taha. (2023) Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study. Frontiers in Neurology 14.
Crossref
Crossref
Hanne van Ballegooijen, Karin van der Hiele, Christian Enzinger, Gert de Voer & Leo H. Visser. (2022) The longitudinal relationship between fatigue, depression, anxiety, disability, and adherence with cognitive status in patients with early multiple sclerosis treated with interferon beta-1a. eNeurologicalSci 28, pages 100409.
Crossref
Crossref
Peter Rieckmann, Tjalf Ziemssen, Iris-Katarina Penner, Alaleh Raji, Torsten Wagner, Joachim Richter & Uwe K. Zettl. (2022) Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart® Injector: Results of the Prospective Cohort Study REBIFLECT. Advances in Therapy 39:6, pages 2749-2760.
Crossref
Crossref
Joshua MardanMohammad Akhtar HussainMichelle AllanLisa B Grech. (2021) Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression. Journal of Managed Care & Specialty Pharmacy 27:9, pages 1273-1295.
Crossref
Crossref
A. Blanco-López, C. Antillón-Ferreira, E. Saavedra-Castillo, M. Barrientos-Pérez, H. Rivero-Escalante, O. Flores-Caloca, R. Calzada-León, C. C. Rosas-Guerra, E. Koledova, E. Chiquete & A. Ayala-Estrada. (2020) Adherence to treatment in children with growth hormone deficiency, small for gestational age and Turner syndrome in Mexico: results of the Easypod™ connect observational study (ECOS). Journal of Endocrinological Investigation 43:10, pages 1447-1452.
Crossref
Crossref
Sergio Sauri-Suárez, Sandra Quiñones-Aguilar, Arturo Contreras-Marín, Erik Omar Ramiro-Guerrero, David Zúñiga-García, Leticia Salinas-Vázquez, Leonardo Llamas-López, Carolina León-Jiménez, Adriana García-Martell, Iliana González-Hernández, Erwin Chiquete & Silvia García. (2020) Adherence to self-administering interferon-β1a using RebiSmart® device in Mexican patients with relapsing multiple sclerosis. PLOS ONE 15:4, pages e0230959.
Crossref
Crossref
L.A. Visser, C. Louapre, C.A. Uyl-de Groot & W.K. Redekop. (2020) Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review. Multiple Sclerosis and Related Disorders 39, pages 101929.
Crossref
Crossref
Rafael Bolaños-Díaz, César Sanabria-Montañez & Nilton Custodio-Capuñay. (2019) Cost-effectiveness of interferon therapy for multiple sclerosis in Peru: impact of treatment adherence. Journal of Pharmaceutical Health Services Research 10:1, pages 125-132.
Crossref
Crossref
Jovana Ivanović, Tatjana Pekmezović & Jelena Drulović. (2019) Interferon beta: Medication which started the revolution in the treatment of multiple sclerosis. Medicinski podmladak 70:1, pages 53-57.
Crossref
Crossref
Peter Rieckmann, Matthias Schwab, Dieter Pöhlau, Iris-Katharina Penner, Torsten Wagner, Elke Schel & Antonios Bayas. (2018) Adherence to Subcutaneous IFN β-1a in Multiple Sclerosis: Final Analysis of the Non-Interventional Study READOUTsmart Using the Dosing Log and Readout Function of RebiSmart®. Advances in Therapy 36:1, pages 175-186.
Crossref
Crossref
Spyros N. Deftereos, Evangelos Koutlas, Efrosini Koutsouraki, Athanassios Kyritsis, Panagiotis Papathanassopoulos, Nikolaos Fakas, Vaia Tsimourtou, Nikolaos Vlaikidis, Antonios Tavernarakis, Konstantinos Voumvourakis, Michalis Arvanitis, Dimitrios Sakellariou & Filippo DeLorenzo. (2018) Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study. BMC Neurology 18:1.
Crossref
Crossref
Martin Vališ & Zbyšek Pavelek. (2017) Multiple sclerosis - escalation therapies and evidence-based medicine. Neurologie pro praxi 18:Suppl.F, pages 13-17.
Crossref
Crossref
Chiara Zecca, Giulio Disanto, Sarah Mühl & Claudio Gobbi. (2017) Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study. BMC Neurology 17:1.
Crossref
Crossref
Donald A. Barone, Barry A. Singer, Lubo Merkov, Mark Rametta & Gustavo Suarez. (2016) Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical Autoinjectors. Neurology and Therapy 5:2, pages 155-167.
Crossref
Crossref
Anthony L Traboulsee, Peter Cornelisseª, Magnhild Sandberg-Wollheim, Bernard MJ Uitdehaag, Ludwig Kappos, Peter J Jongen, Cris S Constantinescu, Elisabetta Verdun di Cantogno & David KB Li. (2016) Prognostic factors for long-term outcomes in relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical 2, pages 205521731666640.
Crossref
Crossref